Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and GEJ adenocarcinoma in the major pharmaceutical markets under study, and neither agent is approved to treat esophageal cancer. Roche/Genentech/Chugai’s Herceptin is the first-line standard of care for HER2-positive metastatic patients, and Eli Lilly’s Cyramza is approved for patients with advanced disease following fluoropyrimidine- and platinum-based therapy. Additionally, two PD-1 inhibitors—Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo (Japan only) and Merck & Co.’s Keytruda (United States only)—are approved to treat third- and later-line gastric and GEJadenocarcinoma. Despite these approvals, the gastroesophageal cancer therapy market is largely untapped and thus represents a lucrative opportunity for drug developers. The late-phase pipeline is buoyant; agents span a range of drug classes and target various gastroesophageal cancer populations associated with significant unmet need. These treatments may soon offer patients a more-optimistic outlook.
- How do current treatment practices differ between esophageal, gastric, and GEJcancer, and which populations provide the greatest drug-treatment opportunities by geography?
- What are interviewed thought leaders’ insights on Herceptin, Cyramza, Keytruda, Opdivo, and chemotherapy? What clinical needs remain unfulfilled, and on which opportunities can developers capitalize?
- Which other immune checkpoint inhibitors (Bavencio, Yervoy, tislelizumab) are expected to be approved and in which disease setting(s), and how will they compete with currently marketed and established therapies?
- What agents with novel mechanisms of action are being assessed in Phase III trials, which populations are they targeting, and how will they impact the gastroesophageal cancer therapy market?
- What are the market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.